Polymerase Chain Reaction for Diagnosing Invasive Aspergillosis: Getting Closer but Still a Ways to Go
Open accessThe DOI matches its Crossref record.
Abstract
The technique of PCR for detection of Aspergillus in human specimens has been around in one form or another for almost 2 decades [1], but it is still regarded as too experimental to use for defining invasive fungal disease [2]. The reasons for not including PCR in the European Organisation for Research on Treatment of Cancer and the Mycoses Study Group criteria are as frustrating as they are manifold but include the lack of standardization and the absence of a commercially available system [3]. Notwithstanding the slow development, there have been advances, as attested by the study by White and colleagues in this issue of the journal [4]. This group is based in Cardiff, United Kingdom, and has employed a modified PCR method from a previous coworker [5] for use in a clinical setting. Their primary aim was to assess the performance of PCR in terms of diagnosing invasive aspergillosis, and they succeeded in supporting the value of a negative PCR result for ruling out IA, thereby helping to limit empirical therapy to those patients who are most likely to have the disease. The authors went to a great deal of trouble to undertake the study. They took the British Society for Medical Mycology's proposed standards of care for patients with invasive fungal infections as their starting point [6] but did not seem to manage to enlist the full cooperation of their hematology colleagues. High-resolution CT scans were recommended for all patients with suspected IA, but the compliance of the clinicians was only 37%. Although no one expects 100% compliance for this patient population, others have shown that this type of imaging is attainable in the majority of cases [7, 8]. Compliance in submitting blood samples for the galactomannan ELISA test twice weekly was also low, ∼50%. This makes estimating the true incidence of IA in this population unreliable and may have led to underdiagnosis of IA. The authors also made every effort to minimize variation in the performance of PCR by choosing whole blood samples, rather than plasma or serum samples, and employing a modified version of the extraction method used by a Tübingen group [9] and the standardized Light Cycler (Roche) method for real-time PCR. In this way, they had an assay capable of reliably detecting the equivalent of 5 cfu of Aspergillus, which is in the same range as found in experimentally infected mice [10]. It is true that they used Aspergillus primers that were different from those employed by others [11–19], choosing instead ones that performed well in a previous study [5]. Nonetheless, their assay was sensitive by any standards, so that a negative result effectively meant the absence of fungal DNA, even though the converse was not the case. The authors succeeded in showing a clear relationship between positivity rates for PCR and those for patients but not those for samples. of the 13 patients with proven or probable IA, 12 (92%) had serial positive PCR results, whereas this was the case for only 6 (15%) of the 40 patients with possible IA and 8 (5%) of the 149 patients at risk who had no evidence of IA. The negative predictive value was 99%, with corresponding sensitivity of 92% and specificity of 95%. The performance of their PCR also compares favorably with that of previous studies, yielding high likelihood ratios of probable/proven IA for a positive test result (table 1). Comparison of different studies of PCR for invasive aspergillosis (IA). Therefore, it is fair to conclude, as the authors did, that failure to detect Aspergillus by PCR in blood specimens obtained twice weekly should allow a wait-and-see approach to be taken, thereby reducing the need for empirical antifungal therapy by ∼50%. This is in line with the recent results of a study from Leuven, Belgium, by Maertens et al. [21], who found that detection of galactomannan 3 times weekly in serum drawn on a daily basis could reduce the need for empirical therapy by at least 78%. What other conclusions can be drawn? It is striking that, as with the development of galactomannan, the progress toward using PCR seems, with the notable exception of a Tokyo group [17, 18], to be a primarily European affair involving a few centers. The researchers who opt to study PCR for screening high-risk patients seem to be not particularly enamored of galactomannan testing, and vice versa. This is a pity because combining these 2 tests, perhaps also with β-D-glucan testing, might, in fact, offer a better means of including or excluding the diagnosis of IA, because each measures different components of fungi. However, it may not be that simple, because Kami et al. [17] showed that PCR detected the presence of Aspergillus earlier than did either galactomannan ELISA or the β-D-glucan test, and, in a later study, the same group found that combining the tests reduced sensitivity [18]. A smaller study [22] indicated why this might be, showing (using a variant of the method of Einsele et al. [13]) that PCR was more sensitive t
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
“practice guidelines [7], for validation of diagnostic tests [8– 13], and for performance of epidemiologic studies [14].”
Self-citationWalsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706
Cordonnier, C., Pautas, C., Maury, S., Vekhoff, A., Farhat, H., Suarez, F., Dhédin, N., Isnard, F., Ades, L., Kuhnowski, F., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/597395 · Cited by 389
Invasive aspergillosis in the intensive care unit
Meersseman, W., Lagrou, K., Maertens, J., & Wijngaerden, E. V. (2007) · Clinical Infectious Diseases · doi:10.1086/518852 · Cited by 366
Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis
Mengoli, C., Cruciani, M., Barnes, R. A., Loeffler, J., & Donnelly, J. P. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70019-2 · Cited by 354
Self-citationAspergillus PCR: One Step Closer to Standardization
White, P. L., Bretagne, S., Klingspor, L., Melchers, W. J. G., McCulloch, E., Schulz, B., Finnstrom, N., Mengoli, C., Barnes, R. A., Donnelly, J. P., et al. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01767-09 · Cited by 296
Self-citationInvasive fungal infections in acute leukemia
Bhatt, V. R., Viola, G. M., & Ferrajoli, A. (2011) · Therapeutic Advances in Hematology · doi:10.1177/2040620711410098 · Cited by 71
Special considerations for the diagnosis and treatment of invasive pulmonary aspergillosis
McCarthy, M. W., & Walsh, T. J. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1340835 · Cited by 8
“Aspergillus PCR Initiative (EAPCRI) [56].”
Influential
Metadata
- Authors
- Donnelly, J. P.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-02-15
- Volume
- 42
- Issue
- 4
- Pages
- 487-489
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2170310786
- Cited by
- 114
- References
- 0
- FWCI
- 9.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.